Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | CLK3 | P49761 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysteamine SCHEMBL11058069 | 0.89 | CNR2 (0.38) | CNR2SMN1; SMN2NOS1CLK1CLK2 | |
| SCHEMBL12088941 | 0.80 | NOS1 (0.36) | CNR2SMN1; SMN2NOS1CLK1CLK2 | |
| SCHEMBL18157890 | 0.78 | CNR2 (0.44) | CNR2KMT2AMEN1ACHEHTR1A | |
| SCHEMBL6840743 | 0.77 | ALDH1A1 (0.44) | SMN1; SMN2NOS1KMT2AKDM4EMEN1 | |
| SCHEMBL15095827 | 0.77 | SMN1; SMN2 (0.37) | SMN1; SMN2NOS1CLK1CLK2CLK3 | |
| SCHEMBL8014414 | 0.77 | CNR2 (0.43) | CNR2ACHEHTR1AHTR2AHTR7 | |
| SCHEMBL32666819 | 0.77 | CNR2 (0.43) | CNR2ACHEHTR1AHTR2AHTR7 | |
| SCHEMBL13593108 | 0.77 | CNR2 (0.43) | CNR2ACHEHTR1AHTR2AHTR7 | |
| SCHEMBL19590951 | 0.77 | SMN1; SMN2 (0.48) | SMN1; SMN2NOS1KMT2AKDM4EMEN1 | |
| Methane SCHEMBL11276226 | 0.75 | CNR2 (0.53) | CNR2SMN1; SMN2KMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653141-B2 | HIV protease inhibiting compounds | ABBVIE INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| US-20120225886-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-09-06 | — | — | US | disclosed |
| US-8193227-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110003827-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2011-01-06 | — | — | US | disclosed |
| CN-1070192-C | Thipyridines for use in control of helicobacter bacteria | BYK GULDEN LOMBERG CHEM FAB (DE) | 2001-08-29 | — | — | CN | disclosed |
| US-6107312-A | BACTERICIDE | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-08-22 | — | — | US | disclosed |
| EP-0683776-B1 | SUBSTITUTED HETEROARYLALKYLTHIOPYRIDINES FOR CONTROLLING HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEM FAB (DE) | 1999-04-07 | — | — | EP | disclosed |
| CN-1155284-A | Thipyridines for use in control of helicobacter bacteria | BYK GULDEN LOMBERG CHEM FAB (DE) | 1997-07-23 | — | — | CN | disclosed |
| US-5587389-A | Substituted heteroarylaklylthiopyridines for controlling helicobacter bacteria | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1996-12-24 | — | — | US | disclosed |
| WO-1996000224-A1 | 4-S- AND N-SUBSTITUTED 6-ALKYLPYRIDINES FOR CONTROLLING HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1996-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003827-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | CNR2 4779/4885SMN1; SMN2 4444/4885NOS1 2711/4885 |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | SERPINB1, HPN, DNPEP | CNR2 4779/4885SMN1; SMN2 4444/4885NOS1 2711/4885 |
| US-20120225886-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | CNR2 104/4885SMN1; SMN2 3655/4885NOS1 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.